Table 1 Demographic and clinical features of discovery and validation cohorts
From: THOR is a targetable epigenetic biomarker with clinical implications in breast cancer
Variable | Discovery cohort (n = 17) | Validation cohort (v= 240) | ||
|---|---|---|---|---|
Number | % | Number | % | |
Age | ||||
Mean (range) | 60.3 (41–86) | – | 59 (29–87) | – |
Menopausal status | ||||
Pre-menopausal | 7 | 41.2 | 68 | 28.3 |
Postmenopausal | 10 | 58.8 | 172 | 71.7 |
Histological type | ||||
Ductal | 16 | 94.1 | 195 | 81.3 |
Lobular | 1 | 5.9 | 36 | 15 |
Other | - | - | 9 | 3.7 |
Tumor size | ||||
pT1 | 11 | 64.7 | 134 | 56 |
pT2 | 4 | 23.5 | 101 | 42.1 |
pT3 | 1 | 5.9 | 1 | 0.42 |
pT4 | 1 | 5.9 | 4 | 1.67 |
Lymph nodes | ||||
N0 | 8 | 47.1 | 121 | 50.4 |
N1 | 8 | 47.1 | 75 | 31.3 |
N2 | - | - | 33 | 13.8 |
N3 | 1 | 5.9 | 11 | 4.6 |
Stage (TNM) | ||||
I | 6 | 35.3 | 87 | 36.3 |
II | 8 | 47.1 | 102 | 42.5 |
III | 3 | 17.6 | 44 | 18.3 |
IV | - | - | 7 | 2.9 |
Grade | ||||
1 | 3 | 17.6 | 23 | 9.6 |
2 | 12 | 70.6 | 169 | 70.4 |
3 | 2 | 11.8 | 48 | 20 |
ER status | ||||
Negative | 2 | 11.8 | 59 | 24.6 |
Positive | 15 | 88.2 | 181 | 75.4 |
PR status | ||||
Negative | 7 | 41.2 | 92 | 38.3 |
Positive | 10 | 58.9 | 148 | 61.7 |
HER2 status | ||||
Negative | 13 | 76.5 | 193 | 80.4 |
Positive | 4 | 23.5 | 47 | 19.6 |